Prothena (PRTA) Competitors

ImmunityBio (NASDAQ:IBRX) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Does the MarketBeat Community prefer IBRX or PRTA?

Prothena received 593 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 47.50% of users gave ImmunityBio an outperform vote.

Company	Underperform	Outperform
ImmunityBio	Outperform Votes 19 47.50%	Underperform Votes 21 52.50%
Prothena	Outperform Votes 612 70.43%	Underperform Votes 257 29.57%

Which has higher valuation and earnings, IBRX or PRTA?

Prothena has higher revenue and earnings than ImmunityBio. Prothena is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$14.75M	143.54	-$583.20M	-$0.63	-3.94
Prothena	$135.16M	3.69	-$147.03M	-$2.30	-4.03

Do institutionals & insiders have more ownership in IBRX or PRTA?

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 9.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is IBRX or PRTA more profitable?

Prothena has a net margin of -90.50% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-8,016.83%	N/A	-110.02%
Prothena	-90.50%	-22.67%	-19.68%

Do analysts prefer IBRX or PRTA?

ImmunityBio currently has a consensus price target of $12.19, indicating a potential upside of 391.43%. Prothena has a consensus price target of $55.00, indicating a potential upside of 493.95%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Prothena	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has more volatility and risk, IBRX or PRTA?

ImmunityBio has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.

Does the media refer more to IBRX or PRTA?

In the previous week, ImmunityBio had 1 more articles in the media than Prothena. MarketBeat recorded 7 mentions for ImmunityBio and 6 mentions for Prothena. Prothena's average media sentiment score of 0.95 beat ImmunityBio's score of 0.63 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prothena beats ImmunityBio on 10 of the 19 factors compared between the two stocks.